{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:19:17Z","timestamp":1787642357343,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02344-8","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:29:23Z","timestamp":1780622963000},"page":"1393-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rovadicitinib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"16","key":"2344_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954\u201370.","journal-title":"Blood"},{"key":"2344_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov A, Blazar BR. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol. 2021;230:108823.","journal-title":"Clin Immunol"},{"key":"2344_CR3","doi-asserted-by":"publisher","unstructured":"Becker IC, Barrachina MN, Lykins J, et al. Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.12.04.626665.","DOI":"10.1101\/2024.12.04.626665"},{"key":"2344_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178032","author":"M Hong","year":"2025","unstructured":"Hong M, Ding D, Zhang M, et al. A first-in-class JAK\/ROCK inhibitor, rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to ruxolitinib: a single-arm, multicenter, open-label, phase Ib study. Eur J Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178032.","journal-title":"Eur J Pharmacol"},{"key":"2344_CR5","unstructured":"Chia Tai Tianqing Pharmaceutical Group. FIC's new drug approved! Chia Tai Tianqing's JAK\/ROCK inhibitor rovaxitinib opens a new paradigm for first-line treatment of myelofibrosis [media release]. 28 Feb 2026. https:\/\/www.sinobiopharm.com\/news-center\/dynamic\/24997.html#submenu."},{"key":"2344_CR6","unstructured":"Chia Tai Tianqing Pharmaceutical Group. Rovadicitinib tablets: Chinese prescribing information. 2026. https:\/\/www.cttq.com\/product\/zhongliu-detail-25452.htm. Accessed 4 May 2026."},{"key":"2344_CR7","unstructured":"Chia Tai Tianqing Pharmaceutical Group. Sino Biopharmaceutical and Sanofi have reached an exclusive licensing agreement for rovaxitinib [media release]. 4 Mar 2026. https:\/\/www.cttq.com\/news\/579375.htm."},{"key":"2344_CR8","doi-asserted-by":"crossref","unstructured":"Zhang W, Liu J, Shi Z, et al. Effect and molecular mechanism of TQ05105, a novel small molecule inhibitor of JAK2 in myeloproliferative neoplasm [abstract no. P1004]. HemaSphere. 2022;6(Suppl 3):1720.","DOI":"10.1097\/01.HS9.0000846884.97738.71"},{"issue":"31","key":"2344_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-025-04754-z","volume":"95","author":"J Dai","year":"2025","unstructured":"Dai J, Cheng Y, Zhou Y, et al. Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects. Cancer Chemother Pharmacol. 2025;95(31):1\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2344_CR10","doi-asserted-by":"crossref","unstructured":"Pan L, Xu Z, Yu W, et al. The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis [abstract no. 799MO]. Ann Oncol. 2024;35(Suppl 2):S596.","DOI":"10.1016\/j.annonc.2024.08.850"},{"issue":"Suppl 1","key":"2344_CR11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood-2023-178956","volume":"142","author":"ZF Xu","year":"2023","unstructured":"Xu ZF, Pan L, Hong ZY, et al. First-in-class JAK\/Rock inhibitor rovadicitinib in myeloproliferative neoplasms: a single arm, multicenter, open-label, phase I\/Ib study [abstract]. Blood. 2023;142(Suppl 1):1829\u201331.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2344_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood-2025-481","volume":"146","author":"CK Chang","year":"2025","unstructured":"Chang CK, Shen XL, Zhou H, et al. Safety and efficacy of the JAK\/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: a phase Ib\/II study [abstract]. Blood. 2025;146(Suppl 1):481\u20132.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2344_CR13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2025-2034","volume":"146","author":"J Huang","year":"2025","unstructured":"Huang J, Zeng T, Yang X, et al. BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: a two-cohort, open-label, phase Ib\/II, multicenter study [abstract]. Blood. 2025;146(Suppl 1):2034.","journal-title":"Blood"},{"issue":"24","key":"2344_CR14","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood.2024026581","volume":"145","author":"YM Zhao","year":"2025","unstructured":"Zhao YM, Luo Y, Shi JM, et al. A first-in-class JAK\/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD. Blood. 2025;145(24):2857\u201372.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2344_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2024-204703","volume":"144","author":"YM Zhao","year":"2024","unstructured":"Zhao YM, Luo Y, Shi JM, et al. JAK\/Rock inhibitor rovadicitinib for glucocorticoid-refractory or-dependent chronic graft-versus-host disease: updated results of multicenter, phase 1b\/2a trial [abstract]. Blood. 2024;144(Suppl 1):97\u20138.","journal-title":"Blood"},{"key":"2344_CR16","unstructured":"Zhao Y, Shi Z, Wu H, et al. JAK\/ROCK inhibition with rovadicitinib suppresses murine and human acute graft-versus-host disease: the results of preclinical and phase 1b study [abstract no. S255]. In: EHA2025 congress. 2025."},{"issue":"Suppl 1","key":"2344_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood-2024-203214","volume":"144","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang JS, Wu L, et al. Rovadicitinib in patients with hemophagocytic lymphohistiocytosis: a single arm, open-label, phase I study [abstract]. Blood. 2024;144(Suppl 1):806\u20137.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02344-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02344-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02344-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:30:56Z","timestamp":1787639456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02344-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02344-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}